Loading…
Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people wi...
Saved in:
| Published in: | British journal of psychiatry 2007-07, Vol.191 (1), p.14-22 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633 |
| container_end_page | 22 |
| container_issue | 1 |
| container_start_page | 14 |
| container_title | British journal of psychiatry |
| container_volume | 191 |
| creator | Davies, Linda M. Lewis, Shôn Jones, Peter B. Barnes, Thomas R. E. Gaughran, Fiona Hayhurst, Karen Markwick, Alison Lloyd, Helen |
| description | There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life.
To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia.
Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice.
Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective.
The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics. |
| doi_str_mv | 10.1192/bjp.bp.106.028654 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70661729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1192_bjp_bp_106_028654</cupid><sourcerecordid>2315592374</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633</originalsourceid><addsrcrecordid>eNqFkc-q1DAUxoso3vHqA7iRgOCuNUnbpHEng__gghtdhyQ9bTO0TUzSuYxP5GOacQYuCCJZJCf5fec74SuKlwRXhAj6Vh98pX1FMKsw7VjbPCp2pOG0JA1rHxc7jDEvCW3xTfEsxkMu64byp8UN4QxTQvGu-LV3MZUwDGCSPcIKMSI3oMGGfI2OFYpg3NqXY34KKlm3IrUm6-PJTC5Zg_qwjfEdChC3OUU0BLcghYJae7fYCD3K8hTcPOdjClbNyK4omsn-dH4KsFp11vrsYdcReefCfELJIR_gaN0WUZqysT89L54Mao7w4rrfFt8_fvi2_1zeff30Zf_-rjQNx6nUWgugivV4YHWjiTGKmLbmQ0cpFoK1ujG4aWkvOqU5CD1Aq8H0ou4aqlld3xZvLn19cD82iEnmbxiYZ7VCHkdyzBjhVPwXbDkWtBNdBl__BR7cFtb8CUlr0raC1rzJFLlQJrgYAwzSB7uocJIEy3PaMqcttc8lk5e0s-bVtfOmF-gfFNd4M4AuwGTH6d4GkMH8iU4SQWRe5x711VctOth-hIfx_u38G4iCxyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315592374</pqid></control><display><type>article</type><title>Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Cambridge Journals Online</source><source>Social Science Premium Collection</source><source>Sociology Collection</source><creator>Davies, Linda M. ; Lewis, Shôn ; Jones, Peter B. ; Barnes, Thomas R. E. ; Gaughran, Fiona ; Hayhurst, Karen ; Markwick, Alison ; Lloyd, Helen</creator><creatorcontrib>Davies, Linda M. ; Lewis, Shôn ; Jones, Peter B. ; Barnes, Thomas R. E. ; Gaughran, Fiona ; Hayhurst, Karen ; Markwick, Alison ; Lloyd, Helen ; CUtLASS team</creatorcontrib><description>There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life.
To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia.
Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice.
Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective.
The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.</description><identifier>ISSN: 0007-1250</identifier><identifier>EISSN: 1472-1465</identifier><identifier>DOI: 10.1192/bjp.bp.106.028654</identifier><identifier>PMID: 17602120</identifier><identifier>CODEN: BJPYAJ</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Adult ; Antipsychotic Agents - economics ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Antipsychotics ; Atypical ; Cost analysis ; Cost effectiveness ; Cost-Benefit Analysis ; Female ; First generation ; Health care expenditures ; Health status ; Humans ; Male ; Mental disorders ; Patients ; Pharmaceutical industry ; Prescription drugs ; Psychiatry ; Psychosis ; Psychotropic drugs ; Quality of life ; Quality-Adjusted Life Years ; Randomized controlled trials ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - economics ; Second generation ; Sensitivity analysis ; Statistics as Topic ; Substance abuse treatment ; United Kingdom</subject><ispartof>British journal of psychiatry, 2007-07, Vol.191 (1), p.14-22</ispartof><rights>Copyright © Royal College of Psychiatrists, 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633</citedby><cites>FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2315592374/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2315592374?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,12846,21394,21395,27924,27925,30999,31000,33611,33612,34530,34531,43733,44115,72960,74221,74639</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17602120$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davies, Linda M.</creatorcontrib><creatorcontrib>Lewis, Shôn</creatorcontrib><creatorcontrib>Jones, Peter B.</creatorcontrib><creatorcontrib>Barnes, Thomas R. E.</creatorcontrib><creatorcontrib>Gaughran, Fiona</creatorcontrib><creatorcontrib>Hayhurst, Karen</creatorcontrib><creatorcontrib>Markwick, Alison</creatorcontrib><creatorcontrib>Lloyd, Helen</creatorcontrib><creatorcontrib>CUtLASS team</creatorcontrib><title>Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy</title><title>British journal of psychiatry</title><addtitle>Br J Psychiatry</addtitle><description>There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life.
To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia.
Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice.
Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective.
The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.</description><subject>Adult</subject><subject>Antipsychotic Agents - economics</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Antipsychotics</subject><subject>Atypical</subject><subject>Cost analysis</subject><subject>Cost effectiveness</subject><subject>Cost-Benefit Analysis</subject><subject>Female</subject><subject>First generation</subject><subject>Health care expenditures</subject><subject>Health status</subject><subject>Humans</subject><subject>Male</subject><subject>Mental disorders</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Prescription drugs</subject><subject>Psychiatry</subject><subject>Psychosis</subject><subject>Psychotropic drugs</subject><subject>Quality of life</subject><subject>Quality-Adjusted Life Years</subject><subject>Randomized controlled trials</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - economics</subject><subject>Second generation</subject><subject>Sensitivity analysis</subject><subject>Statistics as Topic</subject><subject>Substance abuse treatment</subject><subject>United Kingdom</subject><issn>0007-1250</issn><issn>1472-1465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2R</sourceid><sourceid>M2S</sourceid><recordid>eNqFkc-q1DAUxoso3vHqA7iRgOCuNUnbpHEng__gghtdhyQ9bTO0TUzSuYxP5GOacQYuCCJZJCf5fec74SuKlwRXhAj6Vh98pX1FMKsw7VjbPCp2pOG0JA1rHxc7jDEvCW3xTfEsxkMu64byp8UN4QxTQvGu-LV3MZUwDGCSPcIKMSI3oMGGfI2OFYpg3NqXY34KKlm3IrUm6-PJTC5Zg_qwjfEdChC3OUU0BLcghYJae7fYCD3K8hTcPOdjClbNyK4omsn-dH4KsFp11vrsYdcReefCfELJIR_gaN0WUZqysT89L54Mao7w4rrfFt8_fvi2_1zeff30Zf_-rjQNx6nUWgugivV4YHWjiTGKmLbmQ0cpFoK1ujG4aWkvOqU5CD1Aq8H0ou4aqlld3xZvLn19cD82iEnmbxiYZ7VCHkdyzBjhVPwXbDkWtBNdBl__BR7cFtb8CUlr0raC1rzJFLlQJrgYAwzSB7uocJIEy3PaMqcttc8lk5e0s-bVtfOmF-gfFNd4M4AuwGTH6d4GkMH8iU4SQWRe5x711VctOth-hIfx_u38G4iCxyw</recordid><startdate>200707</startdate><enddate>200707</enddate><creator>Davies, Linda M.</creator><creator>Lewis, Shôn</creator><creator>Jones, Peter B.</creator><creator>Barnes, Thomas R. E.</creator><creator>Gaughran, Fiona</creator><creator>Hayhurst, Karen</creator><creator>Markwick, Alison</creator><creator>Lloyd, Helen</creator><general>Cambridge University Press</general><general>RCP</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7TK</scope><scope>7XB</scope><scope>88G</scope><scope>88J</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200707</creationdate><title>Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy</title><author>Davies, Linda M. ; Lewis, Shôn ; Jones, Peter B. ; Barnes, Thomas R. E. ; Gaughran, Fiona ; Hayhurst, Karen ; Markwick, Alison ; Lloyd, Helen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - economics</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Antipsychotics</topic><topic>Atypical</topic><topic>Cost analysis</topic><topic>Cost effectiveness</topic><topic>Cost-Benefit Analysis</topic><topic>Female</topic><topic>First generation</topic><topic>Health care expenditures</topic><topic>Health status</topic><topic>Humans</topic><topic>Male</topic><topic>Mental disorders</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Prescription drugs</topic><topic>Psychiatry</topic><topic>Psychosis</topic><topic>Psychotropic drugs</topic><topic>Quality of life</topic><topic>Quality-Adjusted Life Years</topic><topic>Randomized controlled trials</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - economics</topic><topic>Second generation</topic><topic>Sensitivity analysis</topic><topic>Statistics as Topic</topic><topic>Substance abuse treatment</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davies, Linda M.</creatorcontrib><creatorcontrib>Lewis, Shôn</creatorcontrib><creatorcontrib>Jones, Peter B.</creatorcontrib><creatorcontrib>Barnes, Thomas R. E.</creatorcontrib><creatorcontrib>Gaughran, Fiona</creatorcontrib><creatorcontrib>Hayhurst, Karen</creatorcontrib><creatorcontrib>Markwick, Alison</creatorcontrib><creatorcontrib>Lloyd, Helen</creatorcontrib><creatorcontrib>CUtLASS team</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>ProQuest Psychology Journals</collection><collection>ProQuest research library</collection><collection>ProQuest Social Science Journals</collection><collection>Sociology Database (ProQuest)</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davies, Linda M.</au><au>Lewis, Shôn</au><au>Jones, Peter B.</au><au>Barnes, Thomas R. E.</au><au>Gaughran, Fiona</au><au>Hayhurst, Karen</au><au>Markwick, Alison</au><au>Lloyd, Helen</au><aucorp>CUtLASS team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy</atitle><jtitle>British journal of psychiatry</jtitle><addtitle>Br J Psychiatry</addtitle><date>2007-07</date><risdate>2007</risdate><volume>191</volume><issue>1</issue><spage>14</spage><epage>22</epage><pages>14-22</pages><issn>0007-1250</issn><eissn>1472-1465</eissn><coden>BJPYAJ</coden><abstract>There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life.
To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia.
Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice.
Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective.
The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>17602120</pmid><doi>10.1192/bjp.bp.106.028654</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1250 |
| ispartof | British journal of psychiatry, 2007-07, Vol.191 (1), p.14-22 |
| issn | 0007-1250 1472-1465 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70661729 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Cambridge Journals Online; Social Science Premium Collection; Sociology Collection |
| subjects | Adult Antipsychotic Agents - economics Antipsychotic Agents - therapeutic use Antipsychotic drugs Antipsychotics Atypical Cost analysis Cost effectiveness Cost-Benefit Analysis Female First generation Health care expenditures Health status Humans Male Mental disorders Patients Pharmaceutical industry Prescription drugs Psychiatry Psychosis Psychotropic drugs Quality of life Quality-Adjusted Life Years Randomized controlled trials Schizophrenia Schizophrenia - drug therapy Schizophrenia - economics Second generation Sensitivity analysis Statistics as Topic Substance abuse treatment United Kingdom |
| title | Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A41%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20first-%20v.%20second-generation%20antipsychotic%20drugs:%20results%20from%20a%20randomised%20controlled%20trial%20in%20schizophrenia%20responding%20poorly%20to%20previous%20therapy&rft.jtitle=British%20journal%20of%20psychiatry&rft.au=Davies,%20Linda%20M.&rft.aucorp=CUtLASS%20team&rft.date=2007-07&rft.volume=191&rft.issue=1&rft.spage=14&rft.epage=22&rft.pages=14-22&rft.issn=0007-1250&rft.eissn=1472-1465&rft.coden=BJPYAJ&rft_id=info:doi/10.1192/bjp.bp.106.028654&rft_dat=%3Cproquest_cross%3E2315592374%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c470t-bbb9e2a6d0f634b1cca1c537f82209965b4c0452d98ab7e9bfe5becd93842b633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2315592374&rft_id=info:pmid/17602120&rft_cupid=10_1192_bjp_bp_106_028654&rfr_iscdi=true |